Clinical and Experimental Neuroimmunology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Checkpoint inhibitor induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin lymphoma
ConclusionsWe demonstrate that symptoms of immune checkpoint inhibitor induced encephalitis can be unspecific and radiological findings are often inconspicuous. Thus, cerebrospinal fluid analysis is the most important examination to achieve a correct diagnosis which in turn is decisive for a rapid start of therapy. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - February 15, 2021 Category: Neurology Authors: Nora M öhn, Kurt‐Wolfram Sühs, Yenny Angela, Martin Stangel, Philipp Ivanyi, Gernot Beutel, Ralf Gutzmer, Thomas Skripuletz, Imke Grimmelmann Tags: ORIGINAL ARTICLE Source Type: research

Congress report of 16th International Child Neurology Congress/49th annual Child Neurology Society meeting: Virtual 2020
(Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - February 13, 2021 Category: Neurology Authors: Ayuko Igarashi Tags: CONGRESS REPORT Source Type: research

Inflammation in psychiatry especially focused on depression
AbstractThe etiology of depression remains unclear while, in many aspects, the pathology of depression has recently been reported to be closely associated with inflammation. The inflammatory processes often found in the acute stage of depression may have a profound influence of the prognosis of depression. These processes may account for underlying mechanism between depression and other disorders including metabolic disorders and dementia. The relationship between depression and inflammation may shed new light on the development of new diagnostic and therapeutic strategy for depression. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - February 12, 2021 Category: Neurology Authors: Akira Monji Tags: REVIEW ARTICLE Source Type: research

Practical recognition tools of immunoglobulin  G serum antibodies against the myelin oligodendrocyte glycoprotein‐positive optic neuritis and its clinical implications
In this review, we discuss the clinical and paraclinical features of immunoglobulin  G serum antibodies against myelin oligodendrocyte glycoprotein‐positive optic neuritis in adults, and focus on the distinctive features that can enable its early diagnosis. Therapeutical considerations at the acute stage and for relapse prevention are further deliberated. AbstractMyelin oligodendrocyte glycoprotein (MOG) ‐associated disease is an autoimmune disease of the central nervous system, associated with the presence of immunoglobulin G serum antibodies against MOG. Recent data have allowed characterization of the clinical spe...
Source: Clinical and Experimental Neuroimmunology - February 11, 2021 Category: Neurology Authors: Itay Lotan, Frederike C. Oertel, Claudia Chien, Susanna Asseyer, Friedemann Paul, Hadas Stiebel ‐Kalish Tags: REVIEW ARTICLE Source Type: research

Pure red cell aplasia and re ‐aggravation of myasthenia gravis as a result of early reduction of steroid and immunosuppressant after starting eculizumab: A case report
ConclusionsEculizumab might improve the acute phase of MG symptoms, but early reduction of PSL and TAC can aggravate MG pathology and lead to pure red cell aplasia. Autoimmune mechanisms other than the complement ‐mediated mechanism might be involved in the development of pure red cell aplasia. We suggest that physicians should not reduce PSL and immunosuppressants quickly after eculizumab administration. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - February 4, 2021 Category: Neurology Authors: Jun Yamazaki, Yuki Ueta, Yuki Akiba, Takeshi Taguchi, Masayuki Masuda, Hitoshi Aizawa Tags: CASE REPORT Source Type: research

Recent advances in the understanding of myelin oligodendrocyte glycoprotein antibody –associated disorders
(Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - February 1, 2021 Category: Neurology Authors: Ichiro Nakashima Tags: EDITORIAL Source Type: research

Announcement of 2018 Clinical and Experimental Neuroimmunology Best Article award
Clinical and Experimental Neuroimmunology, EarlyView. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - January 25, 2021 Category: Neurology Authors: Hiroyuki Murai Tags: AWARD ANNOUNCEMENT Source Type: research

Gut Microbiome Dysbiosis Shapes Disease Course in the Different Stages of Multiple Sclerosis
AbstractMultiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS), which is the major neurological disease with onset in young adulthood. Most patients experience signs of relapse with intervals of remission lasting for months to years during their early clinical stage. 　Patients who are staying in this stage are referred to as relapsing‐remitting MS (RRMS). (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - January 20, 2021 Category: Neurology Authors: Daiki Takewaki, Takashi Yamamura Tags: NEW DEVELOPMENTS IN NEUROIMMUNOLOGY Source Type: research

Treatment of mog ‐igg associated disease
AbstractMyelin oligodendrocyte glycoprotein (MOG) IgG associated disease (MOGAD) is increasingly recognised as a distinct nosological entity from aquaporin ‐4 antibody IgG positive neuromyelitis optica spectrum disorder (AQP4‐IgG NMOSD). The advent of highly specific MOG‐IgG cell‐based diagnostic assays have helped to refine our understanding of the clinical spectrum of MOGAD. To date, treatment approaches have been largely extrapolated from AQ P4‐IgG NMOSD experience, but there is growing evidence of distinct differences in treatment response between these conditions. This review summarises the current status an...
Source: Clinical and Experimental Neuroimmunology - January 20, 2021 Category: Neurology Authors: Sarah Healy, Kariem Tarik Elhadd, Emily Gibbons, Dan Whittam, Michael Griffiths, Anu Jacob, Saif Huda Tags: REVIEW ARTICLE Source Type: research

Pure red cell aplasia and re ‐aggravation of myasthenia gravis due to early reduction of steroid and immunosuppressant after starting eculizumab: A case report
ConclusionsEculizumab may improve the acute phase of MG symptoms, but early reduction of PSL and TAC can aggravate MG pathology and lead to PRCA. Autoimmune mechanisms other than the complement ‐mediated mechanism may be involved in the development of PRCA. We suggest that physicians should not reduce PSL and immunosuppressants quickly after eculizumab administration. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - January 19, 2021 Category: Neurology Authors: Jun Yamazaki, Yuki Ueta, Yuki Akiba, Takeshi Taguchi, Masayuki Masuda, Hitoshi Aizawa Tags: CASE REPORT Source Type: research

Pediatric Demyelinating Disease and Anti ‐MOG Antibody
AbstractSignificant progress has been made in the field of pediatric neuroimmunology over the past few years. With the detection of conformationally correct myelin oligodendrocyte glycoprotein (MOG) antibodies using cell ‐based assays, children with different monophasic and relapsing phenotypes have been increasingly described. However, there is still controversy regarding the severity of the disease course and outcome of this emerging and rapidly expanding spectrum of MOG‐associated demyelination. Accumulating evidence seems to identify MOG‐IgG‐associated disorder as a disease entity different from multiple sclero...
Source: Clinical and Experimental Neuroimmunology - January 11, 2021 Category: Neurology Authors: Silvia N. Tenembaum Tags: REVIEW ARTICLE (INVITED) Source Type: research

Congress report of 16th International Child Neurology Congress/ 49th Annual Child Neurology Society Meeting: virtual 2020
Abstract16th International Child Neurology Congress (ICNC) was held October 12 ‐23, 2020 in collaboration with the Child Neurology Society (figure1). Due to the COVID‐19 pandemic, this was the first virtual ICNC. Congress theme is “Sharing Knowledge, Sowing Friendships, Spreading Hope”. The additional theme Together • Apart Virtual 2020 is the perfect concept for thi s congress. The ICNCs have truly set the stage as the key forum which provides the very latest and most relevant updates on child neurologic disorders from a global perspective. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - January 8, 2021 Category: Neurology Authors: Ayuko Igarashi Tags: CONGRESS REPORT Source Type: research